Gilead Drops as Patients Relapse on Hepatitis C DrugBusinessWeekFeb. 17 (Bloomberg) -- Gilead Sciences Inc., which fueled a land grab for hepatitis C therapies with its $ 10.8 billion purchase last year of Pharmasset Inc., dropped as much as 20 percent in early trading after some patients on the acquired ...Gilead disappoints with relapse data in oral Hep C studyFierceBiotechGilead shares fall after study announcementSacramento Beeall 90 news articles »
Health - Google
No comments:
Post a Comment